Clinical Trial Update: The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis [Phase 2]

View source ↗

Summary

A Phase 2 trial update assessing a single dose of GSK962040, a motilin receptor agonist, in adults with gastroparesis associated with type 1 diabetes; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroparesis
• Type 1 Diabetes Mellitus

Drugs mentioned

• GSK962040

Snippet

Sponsor: GlaxoSmithKline | Conditions: Gastroparesis | Phase 2 | Status: COMPLETED